
In the “real world” NABUCCO trial, results with nab-paclitaxel were consistent with those reported in the pivotal trial among patients with metastatic breast cancer who are ineligible to receive anthracycline therapy.

In the “real world” NABUCCO trial, results with nab-paclitaxel were consistent with those reported in the pivotal trial among patients with metastatic breast cancer who are ineligible to receive anthracycline therapy.

Toxicities associated with capecitabine may be better managed by dose reductions and/or a week-on/week-off (WOWO) dosing schedule among patients aged 70 years or older with metastatic breast cancer.

The addition of palbociclib (Ibrance) to endocrine therapy led to a consistent improvement in progression-free survival (PFS), according to a biomarker analysis of a recently reported randomized trial.<sup>1</sup>

Alessandra Ferrajoli, MD, discusses the challenge with secondary malignancies in patients with CLL.

James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.

The combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with advanced/refractory genitourinary cancers demonstrated promising activity in the second-line setting and beyond at all dose levels tested.

A new drug application for brigatinib for patients with metastatic ALK-positive NSCLC who are resistant to prior crizotinib (Xalkori) has been granted priority review by the FDA.

The European Medicines Agency (EMA) has accepted and validated a marketing authorization application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

According to an updated survival analysis of the large randomized phase III COMBI-v trial, co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity.

William Cance, MD, has recently joined the University of Arizona Cancer Center (UACC) as Deputy Director.

Dafna Bar-Sagi, PhD, vice dean for science and chief scientific officer of NYU Langone Medical Center, and a senior member of its Perlmutter Cancer Center, was recently named a recipient of the Outstanding Investigator Award from the National Cancer Institute (NCI).

William G. Wierda, MD, PhD, discusses provided his expert insight on the frontline treatment of patients with CLL.

A recent phase III trial showed custirsen combined with docetaxel failed to significantly extend overall survival (OS) compared with docetaxel alone as a second-line treatment for patients with NSCLC.

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Robert S. Alter, MD discusses optimal sequencing for bladder cancer agents and how he determines the appropriate treatment for patients.

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Charles S. Fuchs, MD, MPH, has been appointed the new director and physician-in-chief of Smilow Cancer Hospital at Yale Cancer Center (YCC) in New Haven, Connecticut.

In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.

An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin has been approved by the European Commission (EC) for patients with metastatic pancreatic adenocarcinoma.

James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer research.

In a recent study, single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced <em>BRAF</em>-positive ovarian cancer.

Denosumab (Xgeva) was shown to be noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma.

In an interview with<em> Targeted Oncology</em>, Kimberly L. Blackwell, MD, discusses the latest therapeutic developments for patients with HER2-positive breast cancer while providing insight on the hurdles that still remain.


Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non­–small cell lung cancer (NSCLC) whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Findings of the phase III KEYNOTE-045 trial showed pembrolizumab (Keytruda) demonstrated improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer.